EYPT vs. QTRX, PACB, LAB, CTKB, NAUT, MLYS, PHAR, LYEL, HLVX, and DH
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include Quanterix (QTRX), Pacific Biosciences of California (PACB), Standard BioTools (LAB), Cytek Biosciences (CTKB), Nautilus Biotechnology (NAUT), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), Lyell Immunopharma (LYEL), HilleVax (HLVX), and Definitive Healthcare (DH). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.
In the previous week, EyePoint Pharmaceuticals had 17 more articles in the media than Quanterix. MarketBeat recorded 23 mentions for EyePoint Pharmaceuticals and 6 mentions for Quanterix. EyePoint Pharmaceuticals' average media sentiment score of 1.01 beat Quanterix's score of 0.27 indicating that Quanterix is being referred to more favorably in the media.
Quanterix currently has a consensus target price of $30.60, indicating a potential upside of 78.11%. EyePoint Pharmaceuticals has a consensus target price of $33.71, indicating a potential upside of 183.55%. Given Quanterix's higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than Quanterix.
EyePoint Pharmaceuticals received 184 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 69.81% of users gave EyePoint Pharmaceuticals an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Quanterix has higher revenue and earnings than EyePoint Pharmaceuticals. Quanterix is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -157.77%. EyePoint Pharmaceuticals' return on equity of -10.39% beat Quanterix's return on equity.
Quanterix has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 6.9% of Quanterix shares are owned by company insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Quanterix beats EyePoint Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
